New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 18, 2014
09:00 EDTACRXAcelRx attractive ahead of Zalviso PDUFA, says Roth Capital
Roth Capital believes that AcelRx's Zalviso has the potential to replace IV PCA across many U.S. hospitals for treating patients with moderate-to-severe pain. The firm thinks the drug is likely to be approved next week and views the stock's recent weakness as a buying opportunity.
News For ACRX From The Last 14 Days
Check below for free stories on ACRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
11:06 EDTACRXOptions with increasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use